Skip to main content

Oral Ketamine Options for Selected Patients

Considered only in select cases as part of a carefully evaluated and monitored treatment plan.

Oral Ketamine Options for Selected Patients

For carefully selected patients, Meadowlark may consider off-label compounded oral ketamine in troche or orally disintegrating tablet (ODT) form as one part of a monitored psychiatric treatment plan. It is not a first-line treatment and is not appropriate for every patient.

Before prescribing is considered, Meadowlark completes a clinical evaluation and reviews prior treatment, medical and psychiatric safety, other medications, risks, possible benefits, alternatives, limitations, abuse potential, dissociation, sedation, blood pressure effects, and the monitoring plan.

How We Frame Ketamine Care

  • Considered only after careful clinical evaluation.
  • Not a first-line treatment; not a substitute for standard psychiatric care.
  • Risks, benefits, alternatives, and limitations are reviewed in detail.
  • Informed consent is required.
  • Monitoring expectations are clearly defined.
  • Patients experiencing suicidal intent, psychosis, mania, severe intoxication, substance misuse concerns, or medical instability may require a higher level of care or emergency evaluation.

Why We Are Careful With Compounded Ketamine

Ketamine may be helpful for select patients, but it requires careful screening, dosing boundaries, monitoring, and safety planning. Meadowlark Mind & Body does not use compounded ketamine as a casual wellness product, a first-line treatment, or a substitute for standard psychiatric care. When considered, it is part of a monitored psychiatric treatment plan with informed consent.

We do not prescribe compounded ketamine to: patients with active suicidal ideation requiring emergency intervention, active psychosis, mania, severe untreated substance use disorder, significant cardiovascular instability, or patients who are seeking ketamine as a primary or stand-alone treatment without engaging in appropriate psychiatric care.

Related: Spravato

For appropriate adults with treatment-resistant depression, Spravato® is an FDA-approved esketamine nasal spray that may be discussed as a treatment option. Spravato requires in-office administration and monitoring, and MMB follows applicable Spravato REMS safety requirements.

Ketamine and Spravato Safety Disclaimer

Spravato® is only available after an appropriate clinical evaluation and is not appropriate for every patient. Treatment requires in-office administration and monitoring. Meadowlark Mind & Body follows applicable Spravato REMS safety requirements.

In select cases, off-label compounded ketamine may be considered as part of a carefully monitored treatment plan. Compounded ketamine is not FDA-approved for the treatment of depression, anxiety, or other psychiatric conditions and is not appropriate for every patient. Risks, benefits, alternatives, limitations, abuse potential, dissociation, sedation, blood pressure effects, safety concerns, and monitoring expectations are reviewed before treatment. Patients experiencing suicidal intent, psychosis, mania, severe intoxication, substance misuse concerns, or medical instability may require a higher level of care or emergency evaluation.